Sensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.4% – Here’s Why

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares were up 5.4% during trading on Tuesday . The company traded as high as $33.87 and last traded at $34.5250. 9,984 shares traded hands during trading, a decline of 95% from the average daily volume of 211,519 shares. The stock had previously closed at $32.77.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on FTH shares. Citizens Jmp assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 target price for the company. Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 target price on the stock. Finally, JonesTrading assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Price Performance

The firm has a market cap of $1.01 billion, a PE ratio of -0.28 and a beta of -0.28. The stock has a fifty day simple moving average of $29.23.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, equities analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson purchased 9,391 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. This trade represents a 53.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 49,494 shares of company stock worth $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several large investors have recently made changes to their positions in the business. Citadel Advisors LLC bought a new position in Sensei Biotherapeutics during the second quarter worth $307,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics in the 2nd quarter worth $3,610,000. Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the 1st quarter worth $22,758,000. Bank of America Corp DE increased its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.